Citation only
via OpenAlex
P3205New features of use of moxonidine as telomerase activator
О. Н. Ткачева, Е. N. Dudinskaya, Ekaterina V. Bazaeva
European Heart Journal · 2018 · ▲ 1 citations
Abstract
Introduction: In recent years higher amounts of data are increasingly accumulated highlighting the significance of cellular senescence(definition) in the development of vascular aging. One of the main theories of cellular senescence rests on telomere(definition) shortening. Apart from arterial hypertension, insulin resistance and its associated chronic low-grade inflammation are suggested to play a pivotal role in the shortened telomere length. Assessment of telomerase activity (TA) enables to gain insight into the rate of human aging. It is believed that cellular markers of aging, such as TA, may serve as an additional criterion for evaluation of long-term treatment effectiveness in patients with arterial hypertension. Objective: To study the effect of moxonidine versus bisoprolol on cellular senescence processes in postmenopausal women with arterial hypertension (AH). Materials and methods: The study group was comprised of 56 women with AH and mean age of 63±9.217 years, with SBP of 146.72±7.127 mm Hg and DBP of 84.38±7.941 mm Hg, who received moxonidine treatment (average dose 0.515 mg/day [0.4; 0.6]) for 12 months. Control group was comprised of 59 female patients with AH and mean age of 61±9.117 years, with SBP of 145.59±6.102 mm Hg and DBP of 86.18±6.682 mm Hg, who received treatment with bisoprolol (average dose 5.0 mg/day [5.0; 7.5]) for 12 months. For all patients the measurement of telomerase activity was performed using genomic DNA real-time PCR at baseline and after 12 months of treatment. Statistical analysis was carried out using the SPSS/PASW Statistics software (version 18, SPSS Inc., Chicago, Illinois, USA).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/eurheartj/ehy563.p3205
- Canonical
- link ↗
- Fetched
- 2026-10-10 MST
Cite this
APA
Ткачева, �.�., Dudinskaya, �.N., & Bazaeva, E.V. (2018). P3205New features of use of moxonidine as telomerase activator. <em>European Heart Journal</em>. https://doi.org/10.1093/eurheartj/ehy563.p3205
Vancouver
Ткачева ��, Dudinskaya �N, Bazaeva EV. P3205New features of use of moxonidine as telomerase activator. European Heart Journal. 2018. doi:10.1093/eurheartj/ehy563.p3205.
BibTeX
@article{2018PNewfe,
title = {P3205New features of use of moxonidine as telomerase activator},
author = {О. Н. Ткачева and Е. N. Dudinskaya and Ekaterina V. Bazaeva},
journal = {European Heart Journal},
year = {2018},
doi = {10.1093/eurheartj/ehy563.p3205},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Aging Neuroscience 2018
Open access · CC-BY
Evaluation of Metformin on Cognitive Improvement in Patients With Non-dementia Vascular Cognitive Impairment and Abnormal Glucose Metabolism
The FASEB Journal 2013
Citation only
A new pleiotropic effect of statins in elderly: modulation of telomerase activity
Research Square 2022
Preprint · CC-BY
Prevalence of arterial stiffness and factors associated with arterial stiffness in rheumatoid arthritis patients without cardiovascular disease symptoms: a cross- sectional study
Circulation 2002
Open access · OA
Constitutive Human Telomerase Reverse Transcriptase Expression Enhances Regenerative Properties of Endothelial Progenitor Cells
SciVision Biotech Inc. 2021
Open access · US-GOV
The Evaluation of the Safety and Effectiveness of ANIMERS Chiara LA and JUVÉDERM VOLUMA® for Aging Mid-Face
National Taipei University of Nursing and Health Sciences 2025
Open access · US-GOV